CD5 CAR Immune Cells for Cancer Treatment
Summary
The USPTO has published patent application US20260108608A1, filed October 4, 2023, for CD5-targeting chimeric antigen receptor (CAR) immune cells co-expressing OX40 ligand and IL-15. The application claims immune cells demonstrating synergistic tumor cell-killing activity with improved viability and in vitro proliferation rates as an anticancer cell therapy. Inventors include Seung Min Kim, Eunsol Lee, Hyun Seung Sun, Hansol Kim, Sunglim Cho, Miyoung Jung, and Bokyung Min. The claimed composition is directed to treating CD5-positive tumors including lymphocytic leukemia.
“The present invention relates to immune cells co-expressing a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain and IL-15, and a composition for preventing or treating cancer comprising the same as an active ingredient.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO published patent application US20260108608A1 for CD5-targeting chimeric antigen receptor immune cells. The application claims immune cells co-expressing a CAR with OX40 ligand as an intracellular signaling domain plus IL-15, demonstrating synergistic tumor cell-killing activity and improved viability and proliferation rates. The composition is directed toward preventing or treating CD5-positive tumors including lymphocytic leukemia.
For parties in the biotechnology and cell therapy space, this publication establishes a prior art date of October 4, 2023 for the disclosed CAR technology. Competitors developing CD5-targeting immune cell therapies should review this application to assess potential freedom-to-operate implications or identify opportunities to design around the claimed constructs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CD5-TARGETING CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING THE SAME
Application US20260108608A1 Kind: A1 Apr 23, 2026
Inventors
Seung Min KIM, Eunsol LEE, Hyun Seung SUN, Hansol KIM, Sunglim CHO, Miyoung JUNG, Bokyung MIN
Abstract
The present invention relates to immune cells co-expressing a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain and IL-15, and a composition for preventing or treating cancer comprising the same as an active ingredient. The immune cells of the present invention not only exhibit synergistic tumor cell-killing activity by co-expression of the chimeric antigen receptor and IL-15, but also have significantly improved viability and in vitro proliferation rate, and thus they may be used as an efficient anticancer cell therapy. In particular, the immune cells of the present invention, when expressing a chimeric antigen receptor targeting CD5, may be applied as an effective therapeutic composition for various CD5-positive tumors, including lymphocytic leukemia.
CPC Classifications
A61K 40/421 A61K 38/2086 A61K 40/15 A61K 40/31 A61P 35/02 C07K 14/5443 C07K 14/7051 C07K 16/2896 C12N 5/0646 A61K 2239/22 A61K 2239/38 A61K 2239/48 C07K 2319/00
Filing Date
2023-10-04
Application No.
19118478
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.